Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...

Microwave ablation plus chemotherapy significantly improves progression-free survival in advanced NSCLC without increasing toxicity compared to chemotherapy alone. The combination treatment leverages ...

Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...

ImmunityBio recently reported positive clinical data from its ANKTIVA (nogapendekin alfa inbakicept) program in non-small ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...